Ryaltris approved in Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis -Bausch Health Companies Inc
Bausch Health Companies Inc. and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. announce that Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older
“This Health Canada approval will allow Bausch Health to soon make Ryaltris available to Canadians, providing an innovative therapy option for seasonal allergic rhinitis,” Cees Heiman, Senior Vice-President, Europe and Canada, Bausch Health said. “This is part of our ongoing commitment to being a trusted partner in the healthcare of Canadians.”
Ryaltris is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes after administration of Ryaltris.
Related news and insights
Novartis has announced the pivotal Phase III PSMAfore study with Pluvicto(INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint
Merck KGaA, a leading science and technology company, and the Pediatric Praziquantel Consortium, announced that the EMA has validated for review the application for arpraziquantel for the treatment of schistosomiasis in preschool-aged children (3 months to 6 years of age)
The FDA has accepted a biologics license application (BLA) seeking the approval of a reformulation of denileukin diftitox (I/Ontak; E7777) for use as a potential therapeutic option in patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL)